4Bardin L,Auclair A,Kleven MS,et al.Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/sepotonin 5-HT1A activity; comparison with typical conventional antipsychotics.Behav pharmacol,2007,18:103-118.
5Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short- term management of agitated psychot- ic patients[ J]. J Clin Psychiatry ,2001,62 ( 1 ) : 12 - 18.
6?,arnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antip- ~ychotic drug[ J]. Pharmacotberapy,2001,21 (6) :717 - 730.
7Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic [ J ]. Ann Pharmacother,2002,36 ( 5 ) : 839 - 851.
